I am an expert in the field of clotting mechanics (US NIH funded research / vascular surgery fellow). Not sure why they chose TEG to monitor coagulation status - it does not reflect well changes from any of the drugs used in the study.
It would be interesting to see the results broken down by gender - females respond much differently to aspirin and have less of a survival benefit than males (don’t get me started, many of the initial trials in the 60’s with aspirin were done with mostly males).
Also, in my own research - we have found that aspirin “softens” clots which allows platelets to squeeze pathological clots to smaller sizes, which allows more recannalization of thrombosed vessels and thus less ischemia - would be interesting to see if that same MOA happens here.
I am an expert in the field of clotting mechanics (US NIH funded research / vascular surgery fellow). Not sure why they chose TEG to monitor coagulation status - it does not reflect well changes from any of the drugs used in the study.
It would be interesting to see the results broken down by gender - females respond much differently to aspirin and have less of a survival benefit than males (don’t get me started, many of the initial trials in the 60’s with aspirin were done with mostly males).
Also, in my own research - we have found that aspirin “softens” clots which allows platelets to squeeze pathological clots to smaller sizes, which allows more recannalization of thrombosed vessels and thus less ischemia - would be interesting to see if that same MOA happens here.